Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights [Yahoo! Finance]
Nuvectis Pharma, Inc. (NVCT)
Company Research
Source: Yahoo! Finance
NXP800 Investigator-sponsored clinical trial in cholangiocarcinoma initiated with the Mayo Clinic NXP800 granted Orphan Drug Designation for the treatment of cholangiocarcinoma NXP900 Phase 1a dose escalation initiated Multiple clinical data readouts expected in 2024 FORT LEE, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the fiscal year 2023 and provided an update on recent business progress. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "2023 was an eventful year for Nuvectis as we continued to make important strides with our two clinical-stage drug candidates, NXP800 and NXP900. For NXP800, we initiated the Phase 1b in platinum resistant ARID1a-mutated ovarian carci
Show less
Read more
Impact Snapshot
Event Time:
NVCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVCT alerts
High impacting Nuvectis Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
NVCT
News
- Nuvectis Pharma: An Interesting Early Pipeline Does Not Justify A Buy [Seeking Alpha]Seeking Alpha
- Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference [Yahoo! Finance]Yahoo! Finance
- Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor ConferenceGlobeNewswire
- Nuvectis Pharma, Inc. (NASDAQ: NVCT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.MarketBeat
- Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights [Yahoo! Finance]Yahoo! Finance
NVCT
Earnings
- 5/7/24 - Beat
NVCT
Analyst Actions
- 5/8/24 - HC Wainwright
NVCT
Sec Filings
- 5/15/24 - Form 4
- 5/13/24 - Form 4
- 5/13/24 - Form 4
- NVCT's page on the SEC website